AN2 Therapeutics Investor Presentation Deck
August 2022, 25 slides
  1. AN2 Therapeutics
  2. Related Decks
  3. Investor Presentation Decks
developing treatments for rare chronic and serious infectious diseases with high unmet needs an therapeutics lei | AN2 Therapeutics
disclaimer an therapeutics | AN2 Therapeutics
corporate overview eric founder president and a an therapeutics | AN2 Therapeutics
team with significant experience in bringing medicines to market i an therapeutics | AN2 Therapeutics
an therapeutics is a clinical stage company developing treatments for rare chronic and serious infectious diseases with high unmet needs we expect our boron chemistry to drive future pipeline of differentiated compounds an therapeutics | AN2 Therapeutics
pipeline targets high unmet needs in rare chronic and serious infectious diseases boron chemistry approach enables targeting of novel biological targets lung disease an therapeutics | AN2 Therapeutics
lung disease an therapeutics | AN2 Therapeutics
lung disease a rare chronic and progressive infectious disease an therapeutics | AN2 Therapeutics
lung disease and growing market opportunity initial indication targeting treatment refractory mac lung disease estimated patients with lung disease in an therapeutics | AN2 Therapeutics
current treatment regimens for patients with complex mac lung disease leave a significant unmet medical need all treatments except are used off label treatment patients treatment refractory patients an therapeutics | AN2 Therapeutics
inhaled first and only approved lung disease drug is associated with a high discontinuation rate and increased adverse events versus soc therapy alone pivotal study convert results convert study parameter control efficacy culture converted by month safety withdrawn from study upper respiratory adverse events an therapeutics | AN2 Therapeutics
novel mechanism of action inhibits the protein synthesis enzyme leucyl by binding to the terminal adenosine ribose of in the editing site leucine an an therapeutics | AN2 Therapeutics
broad activity in activity against clinical isolates of mac with between to range core an therapeutics | AN2 Therapeutics
antibacterial activity in a chronic model of mac lung disease in mice showed improved antibacterial activity of at all doses compared to the daily humanized dose of an therapeutics | AN2 Therapeutics
antibacterial activity in a chronic model of mac lung disease in mice significant reductions in mac with superior decreases with soc regimen compared to soc alone an therapeutics | AN2 Therapeutics
a day phase dose ranging study of oral supports once daily dose for patients with treatment refractory mac lung disease phase design and results once daily dose achieved exposures suggesting high probability of target attainment for treatment of mac lung disease and was well tolerated through day so i generally an therapeutics | AN2 Therapeutics
favorable results from phase trial showed the concentration in lung macrophages site of infection was higher than in plasma pois am | AN2 Therapeutics
a phase pivotal clinical trial of in treatment refractory mac lung disease plan to use pathway in microbiological primary in japan to support potential registration phase part phase part an therapeutics | AN2 Therapeutics
commercial strategy establish treatment refractory market significant growth opportunity in us markets with additional labeled indications reported an therapeutics | AN2 Therapeutics
attractive target product profile to address unmet needs in with potential to become an important component of therapy planned target product profile criteria criteria i therapeutics | AN2 Therapeutics
intellectual property up to years of exclusivity united states japan patents issued in composition of matter patent expires june without hatch waxman extensions pediatric exclusivity up to years of extensions protection up to june orphan drug years gain act years available an therapeutics | AN2 Therapeutics
existing cash funds value driving milestones cash cash equivalents and investments as of an therapeutics | AN2 Therapeutics
our global health commitment global health agreement partners an leadership team is committed to applying our know how to help solve some of the infections in global health intent is to fund these efforts primarily through non dilutive funding from sources such as public and private agencies and foundations the highest priority is currently conducting preclinical research with an university an therapeutics | AN2 Therapeutics
an therapeutics is a clinical stage company developing treatments for rare chronic and serious infectious diseases with high unmet needs we expect our boron chemistry to drive future pipeline of differentiated compounds an therapeutics | AN2 Therapeutics
developing treatments for rare chronic and serious infectious diseases with high unmet needs an therapeutics lei | AN2 Therapeutics
See More
AN2 Therapeutics
Investor Presentation Decks
Biotechnology Decks
Healthcare Decks
Explore Topics
Lung
Recent decks by AN2 Therapeutics
IPO
March 2022
See all presentations by AN2 Therapeutics (2 decks)
Related decks
Genprex
Investor Presentation
October 2022
Genelux
Investor Presentation
December 2023
Genelux
Investor Presentation
February 2024
Genelux
Investor Presentation
July 2023
AstraZeneca
Investor Event
June 2023
Genelux
Investor Presentation
October 2023
AstraZeneca
Investor Conference
April 2023
BioAtla
Investor Presentation
January 2024
Recent decks by AN2 Therapeutics
See all presentations (2 decks)
IPO
March 2022
Genprex
Investor Presentation
October 2022
Genelux
Investor Presentation
December 2023
Genelux
Investor Presentation
February 2024
Genelux
Investor Presentation
July 2023
AstraZeneca
Investor Event
June 2023
Genelux
Investor Presentation
October 2023
AstraZeneca
Investor Conference
April 2023
BioAtla
Investor Presentation
January 2024
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io